Modeling indicates that three children will lose their lives annually due to delays in implementing a blood test for a muscle degenerative condition within the NHS. Documents obtained by the Mirror reveal the severe repercussions of postponing universal screening for spinal muscular atrophy (SMA) in infants. Advocacy is underway for the inclusion of a £5 SMA check in the NHS newborn heel prick test, which currently screens for ten other conditions, such as cystic fibrosis.
While most European countries and the US already test for SMA, the UK’s National Screening Committee has hesitated to recommend newborn SMA screening despite the availability of life-changing treatments since 2019. This delay leads to numerous infants being unnecessarily disabled each year. The Sheffield Centre for Health and Related Research (SCHARR) modeling demonstrates that every year of postponed screening results in three infant fatalities and additional babies requiring respiratory support due to muscle degradation in their lungs and windpipe.
The prolonged absence of screening translates to 30 SMA infants growing up incapable of walking and confined to a seated position. Cost-wise, the investment of £6.7 million in universal newborn SMA screening is projected to yield long-term savings by reducing healthcare expenses. Giles Lomax, CEO of SMA UK charity, highlights the potential benefits of implementing screening, emphasizing superior outcomes and cost-effectiveness compared to the current non-screening approach.
The Mirror’s findings underscore the hidden costs associated with SMA, including expenses related to specialized equipment, home modifications, and lost parental income due to caregiving responsibilities. Notably, infants with severe SMA Type 1 may require constant nursing care to monitor their breathing and support them at school. Additionally, repeat hospitalizations for common infections further burden the NHS.
Health Secretary Wes Streeting is considering expanding an upcoming NHS pilot to include SMA screening for all newborns as part of routine testing. The proposed pilot aims to screen two-thirds of newborns, while the remaining third serves as a control group for outcome comparison, a decision criticized as unethical by experts. Streeting’s potential policy shift follows a meeting with Jesy Nelson, a former Little Mix member whose twin infants face SMA Type 1 diagnosis.
The modeling reveals that SMA screening can enable approximately 37 more babies to lead normal lives, yet it may also diagnose and treat three infants for less severe SMA forms prematurely, potentially impacting their health negatively. Streeting acknowledges the compelling arguments for enhanced screening efforts and promises progress towards a large-scale trial next year to gather evidence supporting a national screening program. The evaluation’s potential acceleration and expansion to encompass all newborns are under review, with updates expected for the SMA community.